0.7304
Schlusskurs vom Vortag:
$0.70
Offen:
$0.71
24-Stunden-Volumen:
1.21M
Relative Volume:
1.18
Marktkapitalisierung:
$69.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-93.61M
KGV:
-0.3462
EPS:
-2.11
Netto-Cashflow:
$-71.16M
1W Leistung:
-17.93%
1M Leistung:
-36.49%
6M Leistung:
-42.49%
1J Leistung:
-42.49%
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Vergleichen Sie IMUX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IMUX
Immunic Inc
|
0.7304 | 85.28M | 0 | -93.61M | -71.16M | -2.11 |
![]()
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-25 | Eingeleitet | William Blair | Outperform |
2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
2021-04-15 | Eingeleitet | Aegis Capital | Buy |
2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
2020-06-05 | Eingeleitet | Wedbush | Outperform |
2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
2020-03-25 | Eingeleitet | ROTH Capital | Buy |
2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering | IMUX Stock News - GuruFocus
Immunic Announces Closing Of Oversubscribed $65 Million Underwritten Public Offering - marketscreener.com
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - Longview News-Journal
Immunic raises $65M in public offering to fund clinical trials - Proactive financial news
Immunic to Participate in Investor, Scientific and Industry Conf - GuruFocus
Immunic Showcases Breakthrough MS Drug Data at 6 Major Healthcare Conferences This Month - Stock Titan
Immunic releases June conference schedule - Proactive Investors
Immunic Announces $65 Million Public Offering - TipRanks
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Eastern Progress
Immunic Inc. prices $65 million public offering By Investing.com - Investing.com South Africa
Immunic (NASDAQ:IMUX) Price Target Lowered to $10.00 at D. Boral Capital - Defense World
Immunic (IMUX) Launches $65M Public Offering, Shares Drop - GuruFocus
Immunic Tumbles After Pricing $65 Million Offering of Warrants - marketscreener.com
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Un - GuruFocus
Small cap wrap: Fineqia, Synchronoss, Santacruz Silver, Immunic... - Proactive financial news
Immunic (IMUX) Receives Target Price Adjustment from D. Boral Ca - GuruFocus
Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering - GuruFocus
Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering | IMUX Stock News - GuruFocus
Immunic (IMUX) Launches Public Offering with Warrant Options | I - GuruFocus
Immunic shares fall 12% after pricing of $65 million underwritten public offering to fund trials - Seeking Alpha
Immunic unveils pricing of $65M underwritten public offering - Proactive financial news
Immunic (IMUX) Launches Public Offering with Warrant Options | IMUX Stock News - GuruFocus
Immunic Announces Pricing Of Oversubscribed $65 Million Underwritten Public Offering - marketscreener.com
Immunic Inc. prices $65 million public offering - Investing.com
Immunic, Inc. Announces Proposed Public Offering - Longview News-Journal
Immunic Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Investing.com Nigeria
Immunic launches public offering of warrants to fund clinical trials; shares down - MSN
Immunic slides on planned equity raise - TradingView
Immunic (IMUX) Launches Public Offering with Pre-Funded and Warr - GuruFocus
Immunic announces public offering of warrants to fund trials By Investing.com - Investing.com India
Immunic (IMUX) Launches Public Offering with Pre-Funded and Warrants | IMUX Stock News - GuruFocus
Immunic Announces Public Offering to Fund Trials - TipRanks
Biotech Immunic Launches Strategic Public Offering to Advance Inflammatory Disease Pipeline - Stock Titan
Immunic's IMU-856 shows promise as Celiac Disease Awareness Month draws to a close - Proactive Investors
Immunic’s (IMUX) Buy Rating Reiterated at B. Riley - Defense World
Analyst Adjusts Target Price for Immunic (IMUX) Amid Strategic F - GuruFocus
Immunic (IMUX) Price Target Lowered by B. Riley Securities | IMU - GuruFocus
Analyst Adjusts Target Price for Immunic (IMUX) Amid Strategic Financing Prospects | IMUX Stock News - GuruFocus
B. Riley Cuts Price Target on Immunic to $5 From $6, Keeps Buy Rating - marketscreener.com
Janus Henderson Group PLC Cuts Stock Holdings in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic, Inc. (NASDAQ:IMUX) Receives $13.20 Average Price Target from Analysts - Defense World
Immunic: Q1 Earnings Snapshot - CT Insider
Barclays PLC Takes $84,000 Position in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic (IMUX) Projected to Post Earnings on Wednesday - Defense World
Immunic CMO on Celiac Disease Awareness Month, potential of IMU-856 - Proactive financial news
Reviewing Psyence Biomedical (NASDAQ:PBM) and Immunic (NASDAQ:IMUX) - Defense World
Immunic eyes Phase 3 after MS disability gains in Phase 2 CALLIPER trial - Proactive financial news
36,811 Shares in Immunic, Inc. (NASDAQ:IMUX) Acquired by Invesco Ltd. - Defense World
Immunic (IMUX) Stock Price, News & Analysis - MarketBeat
Where Do Analysts See Immunic Inc (NASDAQ: IMUX) Heading? - Stocksregister
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):